SGLT2抑制剂药物的研究进展

Research Progress of Sodium-glucose Co-transporter-2 Inhibitor Drugs

钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂是一种能够特异性抑制肾小球近端小管,对滤过葡萄糖重吸收,使过量的葡萄糖从尿液中排出,直接降低血糖的药物。目前临床研究表明,SGLT2抑制剂具有良好的药效、安全性和耐受性,能够有效地降低血糖,增加尿液中葡萄糖的排出量,可能成为一种新的治疗2型糖尿病(T2DM)高血糖的方法。现就SGLT2抑制剂在T2DM治疗方面的最新研究进展予以综述。

Selective inhibitors of sodium-glucose co-transporter-2 （ SGLT2 ） reduce glucose reabsorption, causing excess glucose to be eliminated in the urine, which decreases plasma glucose. Current clinical studies have shown that SGLT2 inhibitors have good efficacy, safety and tolerability, could effectively lower plasma glucose levels. Increasing the excretion of glucose in the urine may become a new treatment for type 2 diabetes mellitus（T2DM）. Here is to make a review on the latest research progress on SGLT2 inhibitors for the treatment of T2DM.